Literature DB >> 24385510

High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target.

Thomas F Lüscher1, Ulf Landmesser, Arnold von Eckardstein, Alan M Fogelman.   

Abstract

High-density lipoprotein (HDL) is a complex mixture of lipoproteins that is associated with many minor proteins and lipids that influence the function of HDL. Although HDL is a promising marker and potential therapeutic target based on its epidemiological data and the effects of healthy HDL in vitro in endothelial cells and macrophages, as well as based on infusion studies of reconstituted HDL in patients with hypercholesterolemia, it remains still uncertain whether or not HDL cholesterol-raising drugs will improve outcomes. Recent studies suggest that HDL becomes modified in patients with coronary artery disease or acute coronary syndrome because of oxidative processes that result in alterations in its proteome composition (proteome remodelling) leading to HDL dysfunction.

Entities:  

Keywords:  apolipoprotein A-I; cholesterol, HDL; nitric oxide

Mesh:

Substances:

Year:  2014        PMID: 24385510     DOI: 10.1161/CIRCRESAHA.114.300935

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  82 in total

Review 1.  Nanoparticle systems for cancer vaccine.

Authors:  Ru Wen; Afoma C Umeano; Yi Kou; Jian Xu; Ammad Ahmad Farooqi
Journal:  Nanomedicine (Lond)       Date:  2019-02-26       Impact factor: 5.307

Review 2.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

3.  High-density lipoprotein attenuates Th1 and th17 autoimmune responses by modulating dendritic cell maturation and function.

Authors:  Ioanna Tiniakou; Elias Drakos; Vaios Sinatkas; Miranda Van Eck; Vassilis I Zannis; Dimitrios Boumpas; Panayotis Verginis; Dimitris Kardassis
Journal:  J Immunol       Date:  2015-04-13       Impact factor: 5.422

Review 4.  The perils of surrogate endpoints.

Authors:  William S Weintraub; Thomas F Lüscher; Stuart Pocock
Journal:  Eur Heart J       Date:  2015-05-13       Impact factor: 29.983

Review 5.  Impact of bariatric surgery on cardiovascular and renal complications of diabetes: a focus on clinical outcomes and putative mechanisms.

Authors:  William P Martin; Neil G Docherty; Carel W Le Roux
Journal:  Expert Rev Endocrinol Metab       Date:  2018-09-19

Review 6.  Invasive coronary imaging: any role in primary and secondary prevention?

Authors:  Carlo Di Mario; Pedro R Moreno
Journal:  Eur Heart J       Date:  2016-03-21       Impact factor: 29.983

7.  High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation.

Authors:  Seth G Thacker; Abdalrahman Zarzour; Ye Chen; Mustafa S Alcicek; Lita A Freeman; Dennis O Sviridov; Stephen J Demosky; Alan T Remaley
Journal:  Immunology       Date:  2016-08-28       Impact factor: 7.397

8.  Circulating oxidized LDL, increased in patients with acute myocardial infarction, is accompanied by heavily modified HDL.

Authors:  Naoko Sawada; Takashi Obama; Shinji Koba; Takashi Takaki; Sanju Iwamoto; Toshihiro Aiuchi; Rina Kato; Masaki Kikuchi; Yuji Hamazaki; Hiroyuki Itabe
Journal:  J Lipid Res       Date:  2020-04-14       Impact factor: 5.922

9.  Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.

Authors:  Yu Kataoka; Jordan Andrews; MyNgan Duong; Tracy Nguyen; Nisha Schwarz; Jessica Fendler; Rishi Puri; Julie Butters; Constance Keyserling; John F Paolini; Jean-Louis Dasseux; Stephen J Nicholls
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

Review 10.  Dysfunctional HDL and atherosclerotic cardiovascular disease.

Authors:  Robert S Rosenson; H Bryan Brewer; Benjamin J Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb
Journal:  Nat Rev Cardiol       Date:  2015-09-01       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.